Almirall, S.A. is a Spanish pharmaceutical company headquartered in Barcelona and founded in 1944. It focuses on the development, production, and marketing of medical dermatology treatments for conditions including atopic dermatitis, psoriasis, acne, and actinic keratosis.
The company operates in more than 100 countries with around 2,100 employees and maintains research, chemical, and pharmaceutical manufacturing facilities. It is publicly listed on the Spanish stock exchange and remains under family influence following a generational leadership transition in 2022.
Almirall holds European rights for certain products, such as EBGLYSS (lebrikizumab), while partners manage commercialization elsewhere. Its activities also encompass related chemical and biotechnological products.
Also known as Almirall SA.
None yet. When a new project in the record names Almirall as owner, partner or investor, it shows here.
Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.
New every‑eight‑week maintenance option offers as few as six injections per year and can be used without mandatory topical therapy from treatment start.
